RecruitingNCT06439303

Analysis and Evaluation of Smoking Treatment With Cytisine

Analysis and Evaluation of Smoking Treatment With Cytisine: Retrospective Observational Study


Sponsor

Regina Elena Cancer Institute

Enrollment

65 participants

Start Date

Mar 20, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The lack of clinical studies on the use of Cytisine in the treatment of the cessation of smoking, the need to find effective therapeutic alternatives and the opportunity to reduce costs related to the complications of cigarette smoking, represent the main reasons that led to the design of this study.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study evaluates the real-world effectiveness of cytisine — a plant-derived medication used to help people quit smoking — in patients with moderate to severe nicotine addiction attending a smoking cessation program. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with moderate to severe tobacco use disorder - Your doctor has prescribed cytisine as part of your quit-smoking treatment - You have attended your first follow-up check-up as scheduled **You may NOT be eligible if...** - You have a medical reason that prevents you from taking cytisine or nicotine receptor drugs - You are currently undergoing drug or radiation treatment for cancer - You are pregnant or breastfeeding - Objective assessment data about your smoking history is unavailable Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCytisine 1,5 mg

Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious


Locations(1)

"Regina Elena" National Cancer Institute

Rome, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06439303